G-Research, a trailblazer in the field of quantitative research and technology, is excited to announce a significant fundraising round that underscores its commitment to innovation in financial markets. While the details of the amount raised remain undisclosed, this funding marks a pivotal moment for the company as it aims to further enhance its infrastructure and expand its capabilities in machine learning and big data analytics. Established with the vision of assembling the brightest minds to tackle complex questions in finance, G-Research leverages cutting-edge technology to anticipate market movements and drive strategic insights for its clients. The capital raised will be strategically allocated towards research initiatives, talent acquisition, and the development of advanced computational tools, reinforcing G-Research's position at the forefront of financial technology. This is an exciting time for the company and its employees, who thrive in a dynamic and collaborative culture that encourages creativity and innovation. G-Research’s commitment to nurturing the talent of its workforce aims to foster world-class ideas that will shape the future of finance. If you are eager to make an impact in a leading environment dedicated to excellence and innovation, G-Research invites you to explore open roles and join their mission to redefine how quantitative research shapes the financial landscape. Stay tuned for more updates as G-Research continues to pave the way for groundbreaking advancements in the world of finance and technology.
Breaking News: G-Research Secures Major Funding to Accelerate Innovation in Quantitative Research and Technology
Get the full G-Research company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Texas Automated Robotics Systems, LLC
Tars Robotics, based in Houston Texas, strives to equip manufacturers with the highest quality robotic automation equipment at the most economical value in the industry. Our goal is to enable as many American manufacturers with the ability to compete in the global injection molding industry. We continue to support the initiative to re-shore products from all industries back to the United States. We offer a wide and unique line of robotic arms for machines ranging from 30 tons to 4,000 tons while providing the best solutions no matter how intelligible or complex. With our customer’s need in mind, our product lines include a diverse series of robots designed for sprue and parts removal, insert molding, de-gating, in-mold labeling, and parts stacking.
$513.0M Seed
today
Viseur AI - Digital Pathology Platform
Viseur AI is a digital pathology and medical imaging platform built to become the operating system of AI-enabled diagnostics. We unify Pathology Information Management (PIMS), Digital Pathology / WSI viewing (IMS), AI model deployment and governance, and enterprise-grade integrations into a single, vendor-agnostic platform designed for real clinical workflows. Healthcare systems and diagnostic labs struggle with fragmented pathology workflows, scanner-locked software, and AI solutions that rarely reach routine clinical use. Viseur AI addresses this by delivering an end-to-end digital pathology platform from specimen to report, combining enterprise-grade WSI viewing, AI model deployment and management, on-prem or hybrid architectures aligned with data privacy and regulatory requirements, and deep LIS, HIS, and PACS integrations that enable standardised and scalable operations across multiple sites. Certified under ISO 13485, ISO 27001, and ISO/IEC 15504-SPICE, Viseur AI creates a foundation for clear and compatible AI in healthcare.
$350.0K Seed
today
Imperagen
Imperagen is advancing enzyme engineering through an integrated, AI-driven platform that enables faster and more precise development of high-performance enzymes. By combining advanced computational modeling with automated lab testing, we help companies improve production processes while reducing cost, time, and environmental impact. Founded by researchers from the Manchester Institute of Biotechnology, Imperagen brings together expertise in physics-based simulation, machine learning, and high-throughput experimentation. Our closed-loop platform continuously learns from real-world data, allowing us to design, test, and refine enzymes with greater accuracy and efficiency than traditional approaches . We take a problem-specific approach, tailoring each solution to the unique requirements of a given enzyme, reaction, and application. We work with organizations across pharma, life sciences, chemicals, food, and consumer goods to solve complex enzyme engineering challenges. Our approach helps reduce development risk, shorten timelines, and support the shift toward more sustainable, enzyme-based manufacturing. Get in touch to learn more about our innovative platform and discover how we can quickly transform your enzyme needs into market-ready solutions.
$6.4M Seed
today
Omni
Omni is an AI analytics platform that empowers everyone—regardless of technical ability—to easily analyze data using AI, spreadsheets, SQL, or point-and-click interfaces. It is built on a semantic layer that makes sure every insight is accurate and dependable. Beyond powering internal analytics, Omni makes it easy for businesses to offer highly customizable in-product analytics to their customers.
$120.0M Series c
today
Moment
The largest RIAs, broker dealers, and private banks trust Moment to power investment management for their traders and advisors. Founded by former fixed income quants from Citadel and Jane Street and backed by over $50M in funding from the world’s leading investors, Moment has developed the first operating system built specifically for wealth management. With Moment’s solution, advisors can build personalized portfolios in seconds, traders can set rules to automatically execute orders at all of the major trading venues, and portfolio managers can automate reinvestment, rebalancing, and compliance monitoring. Moment is headquartered in the Financial District of New York City. Learn more below and follow the team’s rapid growth here on LinkedIn.
$78.0M Series c
today